Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Insights into therapeutic products, preclinical research models, and clinical trials in cardiac regenerative and reparative medicine: where are we now and the way ahead. Current opinion paper of the ESC Working Group on Cardiovascular Regenerative and Reparative Medicine

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Grigorian-Shamagian, L, Sanz-Ruiz, R, Climent, A, Badimon, L, Barile, L, Bolli, R, Chamuleau, S, Grobbee, DE, Janssens, S, Kastrup, J, Kragten-Tabatabaie, L, Madonna, R, Mathur, A, Menasché, P, Pompilio, G, Prosper, F, Sena, E, Smart, N, Zimmermann, W-H & Fernández-Avilés, F 2021, 'Insights into therapeutic products, preclinical research models, and clinical trials in cardiac regenerative and reparative medicine: where are we now and the way ahead. Current opinion paper of the ESC Working Group on Cardiovascular Regenerative and Reparative Medicine', Cardiovascular Research, vol. 117, no. 6, pp. 1428-1433. https://doi.org/10.1093/cvr/cvaa337

APA

Grigorian-Shamagian, L., Sanz-Ruiz, R., Climent, A., Badimon, L., Barile, L., Bolli, R., Chamuleau, S., Grobbee, D. E., Janssens, S., Kastrup, J., Kragten-Tabatabaie, L., Madonna, R., Mathur, A., Menasché, P., Pompilio, G., Prosper, F., Sena, E., Smart, N., Zimmermann, W-H., & Fernández-Avilés, F. (2021). Insights into therapeutic products, preclinical research models, and clinical trials in cardiac regenerative and reparative medicine: where are we now and the way ahead. Current opinion paper of the ESC Working Group on Cardiovascular Regenerative and Reparative Medicine. Cardiovascular Research, 117(6), 1428-1433. https://doi.org/10.1093/cvr/cvaa337

CBE

Grigorian-Shamagian L, Sanz-Ruiz R, Climent A, Badimon L, Barile L, Bolli R, Chamuleau S, Grobbee DE, Janssens S, Kastrup J, Kragten-Tabatabaie L, Madonna R, Mathur A, Menasché P, Pompilio G, Prosper F, Sena E, Smart N, Zimmermann W-H, Fernández-Avilés F. 2021. Insights into therapeutic products, preclinical research models, and clinical trials in cardiac regenerative and reparative medicine: where are we now and the way ahead. Current opinion paper of the ESC Working Group on Cardiovascular Regenerative and Reparative Medicine. Cardiovascular Research. 117(6):1428-1433. https://doi.org/10.1093/cvr/cvaa337

MLA

Vancouver

Author

Grigorian-Shamagian, Lilian ; Sanz-Ruiz, Ricardo ; Climent, Andreu ; Badimon, Lina ; Barile, Lucio ; Bolli, Roberto ; Chamuleau, Steven ; Grobbee, Diederick E ; Janssens, Stefan ; Kastrup, Jens ; Kragten-Tabatabaie, Leyla ; Madonna, Rosalinda ; Mathur, Anthony ; Menasché, Philippe ; Pompilio, Giulio ; Prosper, Felipe ; Sena, Emily ; Smart, Nicola ; Zimmermann, Wolfgram-Hubertus ; Fernández-Avilés, Francisco. / Insights into therapeutic products, preclinical research models, and clinical trials in cardiac regenerative and reparative medicine : where are we now and the way ahead. Current opinion paper of the ESC Working Group on Cardiovascular Regenerative and Reparative Medicine. In: Cardiovascular Research. 2021 ; Vol. 117, No. 6. pp. 1428-1433.

Bibtex

@article{b62f12616f4e4ce8bb158421a140dd35,
title = "Insights into therapeutic products, preclinical research models, and clinical trials in cardiac regenerative and reparative medicine: where are we now and the way ahead. Current opinion paper of the ESC Working Group on Cardiovascular Regenerative and Reparative Medicine",
abstract = "Great expectations have been set around the clinical potential of regenerative and reparative medicine in the treatment of cardiovascular diseases [i.e. in particular, heart failure (HF)]. Initial excitement, spurred by encouraging preclinical data, resulted in a rapid translation into clinical research. The sobering outcome of the resulting clinical trials suggests that preclinical testing may have been insufficient to predict clinical outcome. A number of barriers for clinical translation include the inherent variability of the biological products and difficulties to develop potency and quality assays, insufficient rigour of the preclinical research and reproducibility of the results, manufacturing challenges, and scientific irregularities reported in the last years. The failure to achieve clinical success led to an increased scrutiny and scepticism as to the clinical readiness of stem cells and gene therapy products among clinicians, industry stakeholders, and funding bodies. The present impasse has attracted the attention of some of the most active research groups in the field, which were then summoned to analyse the position of the field and tasked to develop a strategy, to re-visit the undoubtedly promising future of cardiovascular regenerative and reparative medicine, based on lessons learned over the past two decades. During the scientific retreat of the ESC Working Group on Cardiovascular Regenerative and Reparative Medicine (CARE) in November 2018, the most relevant and timely research aspects in regenerative and/or reparative medicine were presented and critically discussed, with the aim to lay out a strategy for the future development of the field. We report herein the main ideas and conclusions of that meeting.",
author = "Lilian Grigorian-Shamagian and Ricardo Sanz-Ruiz and Andreu Climent and Lina Badimon and Lucio Barile and Roberto Bolli and Steven Chamuleau and Grobbee, {Diederick E} and Stefan Janssens and Jens Kastrup and Leyla Kragten-Tabatabaie and Rosalinda Madonna and Anthony Mathur and Philippe Menasch{\'e} and Giulio Pompilio and Felipe Prosper and Emily Sena and Nicola Smart and Wolfgram-Hubertus Zimmermann and Francisco Fern{\'a}ndez-Avil{\'e}s",
note = "Published on behalf of the European Society of Cardiology. All rights reserved. {\textcopyright} The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.",
year = "2021",
month = may,
day = "25",
doi = "10.1093/cvr/cvaa337",
language = "English",
volume = "117",
pages = "1428--1433",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "6",

}

RIS

TY - JOUR

T1 - Insights into therapeutic products, preclinical research models, and clinical trials in cardiac regenerative and reparative medicine

T2 - where are we now and the way ahead. Current opinion paper of the ESC Working Group on Cardiovascular Regenerative and Reparative Medicine

AU - Grigorian-Shamagian, Lilian

AU - Sanz-Ruiz, Ricardo

AU - Climent, Andreu

AU - Badimon, Lina

AU - Barile, Lucio

AU - Bolli, Roberto

AU - Chamuleau, Steven

AU - Grobbee, Diederick E

AU - Janssens, Stefan

AU - Kastrup, Jens

AU - Kragten-Tabatabaie, Leyla

AU - Madonna, Rosalinda

AU - Mathur, Anthony

AU - Menasché, Philippe

AU - Pompilio, Giulio

AU - Prosper, Felipe

AU - Sena, Emily

AU - Smart, Nicola

AU - Zimmermann, Wolfgram-Hubertus

AU - Fernández-Avilés, Francisco

N1 - Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

PY - 2021/5/25

Y1 - 2021/5/25

N2 - Great expectations have been set around the clinical potential of regenerative and reparative medicine in the treatment of cardiovascular diseases [i.e. in particular, heart failure (HF)]. Initial excitement, spurred by encouraging preclinical data, resulted in a rapid translation into clinical research. The sobering outcome of the resulting clinical trials suggests that preclinical testing may have been insufficient to predict clinical outcome. A number of barriers for clinical translation include the inherent variability of the biological products and difficulties to develop potency and quality assays, insufficient rigour of the preclinical research and reproducibility of the results, manufacturing challenges, and scientific irregularities reported in the last years. The failure to achieve clinical success led to an increased scrutiny and scepticism as to the clinical readiness of stem cells and gene therapy products among clinicians, industry stakeholders, and funding bodies. The present impasse has attracted the attention of some of the most active research groups in the field, which were then summoned to analyse the position of the field and tasked to develop a strategy, to re-visit the undoubtedly promising future of cardiovascular regenerative and reparative medicine, based on lessons learned over the past two decades. During the scientific retreat of the ESC Working Group on Cardiovascular Regenerative and Reparative Medicine (CARE) in November 2018, the most relevant and timely research aspects in regenerative and/or reparative medicine were presented and critically discussed, with the aim to lay out a strategy for the future development of the field. We report herein the main ideas and conclusions of that meeting.

AB - Great expectations have been set around the clinical potential of regenerative and reparative medicine in the treatment of cardiovascular diseases [i.e. in particular, heart failure (HF)]. Initial excitement, spurred by encouraging preclinical data, resulted in a rapid translation into clinical research. The sobering outcome of the resulting clinical trials suggests that preclinical testing may have been insufficient to predict clinical outcome. A number of barriers for clinical translation include the inherent variability of the biological products and difficulties to develop potency and quality assays, insufficient rigour of the preclinical research and reproducibility of the results, manufacturing challenges, and scientific irregularities reported in the last years. The failure to achieve clinical success led to an increased scrutiny and scepticism as to the clinical readiness of stem cells and gene therapy products among clinicians, industry stakeholders, and funding bodies. The present impasse has attracted the attention of some of the most active research groups in the field, which were then summoned to analyse the position of the field and tasked to develop a strategy, to re-visit the undoubtedly promising future of cardiovascular regenerative and reparative medicine, based on lessons learned over the past two decades. During the scientific retreat of the ESC Working Group on Cardiovascular Regenerative and Reparative Medicine (CARE) in November 2018, the most relevant and timely research aspects in regenerative and/or reparative medicine were presented and critically discussed, with the aim to lay out a strategy for the future development of the field. We report herein the main ideas and conclusions of that meeting.

UR - http://www.scopus.com/inward/record.url?scp=85105103448&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvaa337

DO - 10.1093/cvr/cvaa337

M3 - Journal article

C2 - 33258961

VL - 117

SP - 1428

EP - 1433

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 6

ER -

ID: 68396856